GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (SZSE:300534) » Definitions » ROC %

Gansu Longshenrongfa Pharmaceutical Industry Co (SZSE:300534) ROC % : 5.57% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Gansu Longshenrongfa Pharmaceutical Industry Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Gansu Longshenrongfa Pharmaceutical Industry Co's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was 5.57%.

As of today (2025-03-28), Gansu Longshenrongfa Pharmaceutical Industry Co's WACC % is 13.71%. Gansu Longshenrongfa Pharmaceutical Industry Co's ROC % is 8.93% (calculated using TTM income statement data). Gansu Longshenrongfa Pharmaceutical Industry Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Gansu Longshenrongfa Pharmaceutical Industry Co ROC % Historical Data

The historical data trend for Gansu Longshenrongfa Pharmaceutical Industry Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gansu Longshenrongfa Pharmaceutical Industry Co ROC % Chart

Gansu Longshenrongfa Pharmaceutical Industry Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.54 0.58 -0.98 7.00 11.88

Gansu Longshenrongfa Pharmaceutical Industry Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.85 9.95 15.58 3.39 5.57

Gansu Longshenrongfa Pharmaceutical Industry Co ROC % Calculation

Gansu Longshenrongfa Pharmaceutical Industry Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=101.318 * ( 1 - 13.57% )/( (677.783 + 796.517)/ 2 )
=87.5691474/737.15
=11.88 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1317.51 - 319.502 - ( 369.244 - max(0, 407.32 - 727.545+369.244))
=677.783

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1336.651 - 378.275 - ( 288.945 - max(0, 485.139 - 646.998+288.945))
=796.517

Gansu Longshenrongfa Pharmaceutical Industry Co's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=57.144 * ( 1 - 29.07% )/( (728.796 + 726.537)/ 2 )
=40.5322392/727.6665
=5.57 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1372.758 - 479.675 - ( 352.993 - max(0, 508.715 - 673.002+352.993))
=728.796

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1373.001 - 497.305 - ( 315.739 - max(0, 513.523 - 662.682+315.739))
=726.537

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gansu Longshenrongfa Pharmaceutical Industry Co  (SZSE:300534) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Gansu Longshenrongfa Pharmaceutical Industry Co's WACC % is 13.71%. Gansu Longshenrongfa Pharmaceutical Industry Co's ROC % is 8.93% (calculated using TTM income statement data). Gansu Longshenrongfa Pharmaceutical Industry Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Gansu Longshenrongfa Pharmaceutical Industry Co ROC % Related Terms

Thank you for viewing the detailed overview of Gansu Longshenrongfa Pharmaceutical Industry Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gansu Longshenrongfa Pharmaceutical Industry Co Business Description

Traded in Other Exchanges
N/A
Address
No. 10, Guofang Road, Dingyuan Town, Yuzhong County, Gansu Province, Lanzhou, CHN, 730102
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd is mainly engaged in the pharmaceutical business. It is engaged in the research and development of new drugs, traditional Chinese medicine processing and production. Its products portfolio includes Yuan Hu Zhitong Dripping Pills, Qiwei Wenyang Capsule and Xiaoshuan Tongluo Tablets. Its products are used to adjust gas, promote blood circulation, relieve pain, relieve cough, eliminate phlegm, relieve asthma, clear heat and dispel dampness, among others.
Executives
Chen Yao Wu Executives
Zhang Jin De Director
Zhang Fan Executives
Kong Jian Feng Executives
Yue Qing Xin Supervisors
Kang Yong Hong Executives

Gansu Longshenrongfa Pharmaceutical Industry Co Headlines

No Headlines